News & Media

IMC Supports National Biomanufacturing and Life Sciences Strategy Commitment to Ensuring Best-In-Class Regulation

Ottawa, July 28, 2021 – Innovative Medicines Canada (IMC) is the national voice for Canada’s innovative pharmaceutical industry. Our members produce many of the vaccines, medicines, and diagnostics that are enabling Canada to emerge from the global pandemic that continues to have a devastating impact on the health and prosperity of Canadians.

Today, Innovation, Science and Economic Development Canada (ISED) and Health Canada launched Canada’s Biomanufacturing and Life Sciences Strategy. This five-pillar national strategy signals the federal government’s commitment to collaborating with industry and other stakeholders in ensuring a robust life sciences sector to develop and deliver innovative medicines and vaccines.

Our common goal is to support the health of all Canadians. IMC and its members applaud the announcement of a national strategy and remain committed to being a trusted partner in building a strong life sciences sector in Canada. IMC members support increasing domestic capacity, growing a competitive sector, and developing a robust biomanufacturing ecosystem.

-Innovative Medicines Canada